we pave the way for biotechs


Berlin Cures: Novel treatment targeting the cause of heart failure

2014-11-05 / Ascenion receives equity in Charité and MDC spin-off Berlin Cures is the first joint spin-off to be launched by the Charité – Universitätsmedizin Berlin (Charité) and the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch. The company is developing a new aptamer-based causal treatment for heart failure. Ascenion, the technology transfer partner of both institutes, has negotiated the licensing and investment agreements, thereby acquiring shares in Berlin Cures.

Further information

Back to the list

Campus Berlin-Buch
Berlin Buch